Trending...
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
EXCELSIOR, Minn. - eTravelWire -- NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience. As part of the collaboration, Corundum will provide resources, including the initial investment in a NeuraWorx seed funding round, aimed at advancing product development and initiating a clinical feasibility study to explore the efficacy and safety of its Cerebrovascular Pacing SystemTM novel technology.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on eTravel Wire
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on eTravel Wire
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on eTravel Wire
- NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
- Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
- Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on eTravel Wire
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Documentary Film "The Story Of Art In Alaska" streaming on Prime Video
- Orion Retreats: Pioneering the Future of Conscious Leadership and Luxury Wellness Tourism
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
Source: NeuraWorx Medical Technologies, Inc.
0 Comments
Latest on eTravel Wire
- BK Adventure Announces Wild New Bioluminescent Kayak Tour Near Cocoa Beach
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- "Retroville RV Park Rolls into Summer with 1960s Drive-In Movie Magic on the Florida Gulf Coast"
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings